All In Biotech

Drug Trial Radar · NCT06251089

Effect of Cetylpyridinium Chloride (CPC) Rinse in Viral Upper Respiratory Tract Infections (vURTI)

Randomized, Double-blind, Multicenter Pilot Clinical Trial to Evaluate the Use of a Mouthwash With Cetylpyridinium Chloride (CPC) in the Prevention and Reduction of Symptoms of Viral Upper Respiratory Tract Infections (vURTI)

Last checked: Nov 20, 2026Latest source record: Aug 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Nov 15, 2023

Primary completion

Aug 5, 2024

Study completion Aug 5, 2024

Sponsor

Lead sponsor
Dentaid SLIndustry
Sponsor type
Industry
Collaborators
Methodex
First posted
Feb 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, controlled clinical trial with two parallel groups in which 150 volunteers (75 per group) will receive either VITIS CPC Protect® mouthwash (Mouthwash with cetylpyridinium chloride (CPC) as an anti-plaque antiseptic at a concentration of 0.07%) or mouthwash without cetylpyridinium chloride, as control group Subjects included in the study will be followed for 90 days. Symptoms associated with vURTIs (viral upper respiratory tract infections) should be recorded, when they appear, to determine the existence of viral infections of the upper respiratory tract. Symptoms and adverse effects will be recorded when the episode occurs. The assignment as VURIs will be made by the investigator once the diaries have been completed, or during the symptoms if possible.

Conditions

  • Viral Pharyngitis

Interventions

  • CPC mouthwashDrug

    0.07% CPC mouthwash

  • PlaceboDrug

    placebo of the CPC mouthwash

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. occurrence of vURTI episodesTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EAP Baix Llobregat

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.